spravato fda approval

FDA Approves ‘Spravato’ Nasal Spray

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

UPI News on MSN · 4d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

Hosted on MSN · 3d

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.

J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care

New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...

mic4d

A Nasal Spray For Depression? FDA Gives Its Approval

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive ...

Hosted on MSN1d

FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Does Medicare cover ketamine infusions for mental health conditions?

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results